Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes Than with Either Monotherapy in Patients with Early Rheumatoid Arthritis: 8-Year Results of An Open-Label Extension of a Phase 3 Trial

被引：0

作者：

Breedveld, Ferdinand C. ^{[1
]}

Keystone, Edward ^{[2
]}

van der Heijde, Desiree ^{[1
]}

Landewe, Robert ^{[3
]}

Smolen, Josef ^{[4
,5
]}

Guerette, Benoit ^{[6
]}

McIlraith, Melissa ^{[6
]}

Kupper, Hartmut ^{[7
]}

Liu, Shufang ^{[8
]}

Wolfe, Benjamin ^{[8
]}

Kavanaugh, Arthur ^{[9
]}

机构：

[1] Leiden Univ, Med Ctr, Leiden, Netherlands

[2] Univ Toronto, Toronto, ON, Canada

[3] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands

[4] Med Univ Vienna, Vienna, Austria

[5] Hietzing Hosp, Vienna, Austria

[6] Abbott, Rungis, France

[7] Abbott GmbH & Co KG, Ludwigshafen, Germany

[8] Abbott, Abbott Pk, IL USA

[9] Univ Calif San Diego, San Diego, CA 92103 USA

来源：

ARTHRITIS AND RHEUMATISM | 2011年 / 63卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1231

引用

页码：S481 / S481

页数：1

共 50 条

[41] LONG-TERM (104-WEEK) EFFICACY AND SAFETY OF APREMILAST MONOTHERAPY IN DMARD-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS: A PHASE 3, RANDOMIZED, CONTROLLED TRIAL AND OPEN-LABEL EXTENSION (PALACE 4)
Wells, A.
Edwards, C.
Adebajo, A.
Kivitz, A.
Bird, P.
Shah, K.
Hu, C.
Aelion, J.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 863 - 864
[42] Long-Term (104-Week) Safety and Efficacy of Monotherapy with Apremilast in DMARD-Naive Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled Trial and Open-Label Extension (PALACE 4)
Wells, Alvin
Edwards, Christopher
Adebajo, Adewale O.
Kivitz, Alan J.
Bird, Paul
Shah, Kamal
Hu, ChiaChi
Stevens, Randall M.
Aelion, Jacob A.
ARTHRITIS & RHEUMATOLOGY, 2014, 66 (12) : 3539 - 3539
[43] Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study
Tanaka, Yoshiya
Yamamoto, Kazuhiko
Takeuchi, Tsutomu
Yamanaka, Hisashi
Ishiguro, Naoki
Eguchi, Katsumi
Watanabe, Akira
Origasa, Hideki
Shoji, Toshiharu
Miyasaka, Nobuyuki
Koike, Takao
MODERN RHEUMATOLOGY, 2014, 24 (05) : 725 - 733
[44] Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial
Rantalaiho, Vappu
Korpela, Markku
Laasonen, Leena
Kautiainen, Hannu
Jarvenpaa, Salme
Hannonen, Pekka
Leirisalo-Repo, Marjatta
Blafield, Harri
Puolakka, Kari
Karjalainen, Anna
Mottonen, Timo
ARTHRITIS RESEARCH & THERAPY, 2010, 12 (03)
[45] Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial
Vappu Rantalaiho
Markku Korpela
Leena Laasonen
Hannu Kautiainen
Salme Järvenpää
Pekka Hannonen
Marjatta Leirisalo-Repo
Harri Blåfield
Kari Puolakka
Anna Karjalainen
Timo Möttönen
Arthritis Research & Therapy, 12
[46] Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial
Bingham, Clifton O., III
Mendelsohn, Alan M.
Kim, Lilianne
Xu, Zhenhua
Leu, Jocelyn
Han, Chenglong
Lo, Kim Hung
Westhovens, Rene
Weinblatt, Michael E.
ARTHRITIS CARE & RESEARCH, 2015, 67 (12) : 1627 - 1636
[47] Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study
Tanaka, Yoshiya
Yamamoto, Kazuhiko
Takeuchi, Tsutomu
Yamanaka, Hisashi
Ishiguro, Naoki
Eguchi, Katsumi
Watanabe, Akira
Origasa, Hideki
Shoji, Toshiharu
Miyasaka, Nobuyuki
Koike, Takao
MODERN RHEUMATOLOGY, 2014, 24 (05) : 734 - 743
[48] Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis
Gladman, Dafna D.
Nash, Peter
Mease, Philip J.
Fitzgerald, Oliver
Duench, Stephanie
Cadatal, Mary Jane
Masri, Karim R.
ARTHRITIS RESEARCH & THERAPY, 2024, 26 (01)
[49] Efficacy and Safety of Tofacitinib in an Open-Label, Long-Term Extension Study in Patients with Psoriatic Arthritis Who Received Adalimumab or Tofacitinib in a Phase 3 Randomized Controlled Study: A Post Hoc Analysis
Gladman, Dafna
Nash, Peter
Mease, Philip J.
FitzGerald, Oliver
Masri, Karim R.
Duench, Stephanie
Jane Cadatal, Mary
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2798 - 2801
[50] Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial
van der Heijde, Desiree
Sieper, Joachim
Maksymowych, Walter P.
Lambert, Robert G.
Chen, Su
Hojnik, Maja
Anderson, Jaclyn K.
Pangan, Aileen L.
ARTHRITIS RESEARCH & THERAPY, 2018, 20

← 1 2 3 4 5 →